Single Agent Vinflunine in the Salvage Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Trial of the Sarah Cannon Research Consortium

Author： Hainsworth John D.   Meluch Anthony A.   Lane Cassie M.   Spigel David R.   Burris Howard A.   Gandhi Jitendra G.   Crane Edward J.   Stipanov Michael A.   Greco F. Anthony  

Publisher： Informa Healthcare

ISSN： 0735-7907

Source： Cancer Investigation, Vol.28, Iss.3, 2010-03, pp. : 275-279

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer

By Oudard Stephane  

Future Oncology, Vol. 7, Iss. 4, 2011-04 ,pp. : 497-506

Future Medicine

Access to resources Recommend Favorite

Phase trial of granulocyte-macrophage colony-stimulating factor plus thalidomide in older patients with castration-resistant prostate cancer

By      

Molecular and Clinical Oncology, Vol. 3, Iss. 4, 2015-01 ,pp. : 865-868

Science Publishers

Access to resources Recommend Favorite

The role of enzalutamide in the treatment of castration-resistant prostate cancer

By Rawlinson Alex   Mohammed Aza   Miller Marek   Kunkler Roger  

Future Oncology, Vol. 8, Iss. 9, 2012-09 ,pp. : 1073-1081

Future Medicine

Access to resources Recommend Favorite

Cytotoxic Compounds in the Treatment of Castration-Resistant Prostate Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 10, 2009-12 ,pp. : 1040-1045

Bentham Science Publishers

Access to resources Recommend Favorite

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer

By Sridhar Srikala   Canil Christina   Chi Kim   Hotte Sebastien   Ernst Scott   Wang Lisa   Chen Eric   Juhasz Agnes   Yen Yun   Murray Peter   Zwiebel James   Moore Malcolm  

Cancer Chemotherapy and Pharmacology, Vol. 67, Iss. 4, 2011-04 ,pp. : 927-933

Springer Publishing Company

Access to resources Recommend Favorite